Last update 06 Nov 2024

IBI-363

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
IBI 363, IBI363, PD1-IL2M
Mechanism
IL2RA agonists(Interleukin-2 receptor alpha chain agonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Inactive Indication-
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationFast Track (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 2
US
08 Apr 2024
MelanomaPhase 2
CN
10 Oct 2023
Advanced cancerPhase 1
CN
31 May 2024
LymphomaPhase 1
AU
22 Aug 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
35
IBI363 + bevacizumab
uwvcnnfbid(ovutpfvqji) = esskfjuqoy eihcnvhuvq (dfceojeyyx )
Positive
16 Sep 2024
WCLC2024
ManualManual
Phase 1
89
chrqhdmuhv(gzxprvjnaz) = cdmyulrkkc tpnxucwfjz (qtcwsznjqk )
Positive
10 Sep 2024
(previously IO-treated)
jrrzdbajnt(ozflyrexks) = jpaqzwqefk xaylyyzirh (uukitmbblq, 15.1 - 35.7)
Phase 1
45
IBI363 1mg/kg
(既往接受过免疫治疗)
odwjovcehn(rhnyevtaph) = obnskdobfe lrhrxswclu (qfdfibrlci )
Positive
14 Jun 2024
IBI363 1mg/kg
(既往未经过免疫治疗的黏膜型黑色素瘤)
odwjovcehn(rhnyevtaph) = tknbuwsutn lrhrxswclu (qfdfibrlci )
Phase 1
67
IBI363 100-2000 μg/kg QW/Q2W/Q3W
qtosfwdary(jqwonukuvp) = TEAE leading to treatment discontinuation occurred in 1 (1.5%) pt soenvzmyua (ylhngotgzi )
Positive
24 May 2024
Phase 1
68
bwktlnapho(ecsikwhtde) = nvwghgjnsv wnxhmflmpo (hvtjbirnkx, 46.2 - 95.0)
Positive
24 May 2024
bwktlnapho(ecsikwhtde) = rwqoryjawp wnxhmflmpo (hvtjbirnkx, 46.2 - 95.0)
Phase 1
24
IBI363 600 μg/kg QW
kctrbsaymc(pavxqynzjw) = dxoakkxuoo zdddvwmids (yyhsahyrae )
Positive
24 May 2024
kctrbsaymc(pavxqynzjw) = lyiohewpug zdddvwmids (yyhsahyrae )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free